Related Experiment Video
Updated: Jun 18, 2025
09:34
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
1.8K
Target regimen profiles for tuberculosis treatment
Christian Lienhardt1, Kelly E Dooley2, Payam Nahid3
1French National Research Institute for Sustainable Development, Montpellier, France.
Bulletin of the World Health Organization
|July 29, 2024
Summary
The World Health Organization (WHO) updated tuberculosis treatment regimen profiles to guide drug developers. These revised profiles aim for simpler, safer, and more accessible tuberculosis treatments for all patients.
Area of Science:
- Global Health
- Infectious Diseases
- Pharmacology
Background:
- Tuberculosis (TB) treatment requires simpler, shorter, safer, and more accessible regimens.
- The World Health Organization (WHO) established initial TB treatment regimen profiles in 2016.
- Recent advancements necessitate an update to these critical treatment guidelines.
Purpose of the Study:
- To revise and update target regimen profiles for tuberculosis treatment.
- To guide drug developers in creating novel, effective, and accessible TB therapies.
- To address the needs of patients and programmatic requirements globally.
Main Methods:
- Updated landscape analysis of current TB treatments.
- Stakeholder surveys and extensive consultations.
- Modeling studies on impact and cost-effectiveness of new regimens.
Main Results:
- Developed revised target regimen profiles for drug-susceptible, drug-resistant, and pan-tuberculosis.
- Defined minimal and optimal targets for new TB treatments.
- Included considerations for diagnostics, adherence, treatment strategies, and cost.
Conclusions:
- Revised WHO target regimen profiles will guide development of quality-assured, affordable TB treatments.
- These updated profiles aim to meet the needs of populations affected by tuberculosis.
- The revisions support the creation of more effective and accessible TB therapies worldwide.
More Related Videos
Related Concept Videos
01:28Pulmonary Tuberculosis V
176
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
176
01:31Pulmonary Tuberculosis III
316
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
316
01:26Pulmonary Tuberculosis IV
134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
01:29Pulmonary Tuberculosis I
228
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
228
01:28Pulmonary Tuberculosis II
215
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
215
01:15Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K